Investors Say Novo Nordisk Misled Them Over Drug Demand

Novo Nordisk was hit with a proposed securities class action in New Jersey federal court alleging the company misled investors over its revenue outlook for 2025 by allegedly overstating the likelihood...

Already a subscriber? Click here to view full article